Guidelines for the management of type 2 diabetes: is ADA and EASD consensus more clinically relevant than the IDF recommendations?

Diabetes Research and Clinical Practice

Volumn 86, Issue SUPLL.1, 2009, Pages

  Czupryniak, Leszek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Clinical guidelines; Treatment algorithms; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN;

ARTICLE; CANADA; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; CONSENSUS DEVELOPMENT; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; EUROPE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN TREATMENT; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRACTICE GUIDELINE; UNITED STATES;

CONSENSUS; DIABETES MELLITUS, TYPE 2; GUIDELINES AS TOPIC; HUMANS; HYPERGLYCEMIA; INTERNATIONAL COOPERATION; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 72049117102     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(09)70005-1     Document Type: Article

References (19)

1. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52 (2009) 17-30
2. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49 (2006) 1711-1721
3. American Diabetes Association. The American Diabetes Association (ADA) has been actively involved in the development and dissemination of diabetes care standards, guidelines, and related documents for many years. Introduction. Diabetes Care 32 Suppl 1 (2009) S1-S2
4. Ceriello A., Colagiuri S., Gerich J., and Tuomilehto J. Guideline Development Group. Guideline for management of postmeal glucose. Nutr Metab Cardiovasc Dis 18 (2008) S17-S33
5. Clark Jr. C.M., and Kinney E.D. The potential role of diabetes guidelines in the reduction of medical injury and malpractice claims involving diabetes. Diabetes Care 17 (1994) 155-159
6. The National Collaborating Centre for Chronic Conditions. Type 2 diabetes. National Clinical Guideline for Management in Primary and Secondary Care (update). Royal College of Physicians, London, 2008.
7. Andel M., Bolli G.B., Boulton A., Bozikov V., Car N., Christov V., et al. Recommendations for the Management of Patients with Type 2 Diabetes Mellitus in the Central, Eastern and Southern European Region. Consensus Statement. Int J Postgrad Training Med 8 (2000) 1-26
8. Polish Diabetes Association. Clinical guidelines on the management of patients with diabetes 2009. Diabetol Prakt 10 Supl. A (2009) A1-A38
9. Rydén L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28 (2007) 88-136
10. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
11. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
12. Gæde P., Vedel P., Parving H.-H., and Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes and microalbuminuria: the Steno type 2 randomised study. Lancet 353 (1999) 617-622
13. Gæde P., Vedel P., Larsen N., Jensen G.V.H., Parving H.-H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
14. De Hert M., Dekker J.M., Wood D., Kahl K.G., Holt R.I., and Möller H.J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry (2009; Aug 12) 10.1016/j.eurpsy.2009.01.005
15. van Avendonk M.J., Gorter K.J., van den Donk M., and Rutten G.E. Insulin therapy in type 2 diabetes is no longer a secondary care activity in the Netherlands. Prim Care Diabetes 3 (2009) 23-28
16. Eizirik D.L. Guidelines for medical management of hyperglycaemia in type 2 diabetes and duality of interest. Diabetologia 52 (2009) 550-551
17. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
18. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
19. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D., et al. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. N Engl J Med 360 (2009) 129-139